Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TARA Biosystems, acquired by Valo Health in January 2022, specialized in developing highly physiological, human-relevant 'heart-on-a-chip' tissue models using induced pluripotent stem cells (iPSCs). Their advanced Biowire™ II platform generated 3D cardiac tissues that mimic human heart functions, enabling more accurate prediction of drug efficacy and cardiotoxicity. This technology significantly enhances drug discovery and development by providing human-translatable data early in the preclinical phase. As part of Valo Health, TARA's capabilities are integrated into Valo's end-to-end AI-powered drug discovery and development platform, aiming to accelerate the creation of new therapeutics, particularly in cardiovascular diseases.
Primary research and development facility for cardiac tissue engineering and 'heart-on-a-chip' platform technology development. Operations are now integrated with Valo Health.
Formerly located within the Alexandria Center for Life Science, a prominent biotech hub, featuring state-of-the-art laboratory facilities for advanced tissue engineering.
As a pioneering biotech, TARA fostered an innovative, science-driven, and collaborative environment focused on cutting-edge research and development. This spirit is carried forward within Valo Health's R&D environment.
This location served as the birthplace and development hub for TARA's proprietary cardiac tissue modeling technology, crucial for its contributions to predictive drug discovery and reducing attrition in later-stage clinical trials.
Prior to its acquisition, TARA Biosystems engaged in collaborations with pharmaceutical partners internationally. Now integrated into Valo Health, its cutting-edge technology contributes to Valo's broader global strategy in AI-powered drug discovery and development. Valo Health has operations in North America (USA and Canada) and pursues global partnerships and research collaborations. The TARA platform supports these efforts by providing human-relevant data for drug programs with international reach.
450 East 29th Street
New York
NY
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, TARA Biosystems' leadership includes:
TARA Biosystems has been backed by several prominent investors over the years, including:
Following its acquisition by Valo Health in January 2022, TARA Biosystems' executive leadership was integrated into Valo Health. Key personnel, such as former TARA CEO Misti Ushio, assumed significant roles within Valo, overseeing the TARA platform. In the last 12 months, there have been no major public announcements of executive hires or exits specifically for a distinct 'TARA Biosystems' unit, as changes would occur at the Valo Health corporate or divisional level.
Discover the tools TARA Biosystems uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Valo Health, TARA Biosystems likely utilized common professional email formats such as [first_initial][last] or [first].[last] @tarabiosystems.com. Since the acquisition, employees integrated into Valo Health would use Valo Health's standard email domain (@valohealth.com). The formats listed are historical/speculative for the original TARA Biosystems domain.
[first_initial][last]@tarabiosystems.com, [first].[last]@tarabiosystems.com
Format
jdoe@tarabiosystems.com, jane.doe@tarabiosystems.com
Example
70%
Success rate
Valo Health • October 17, 2023
Valo Health announced it would present data from its drug discovery and development platform, including insights from its human tissue modeling platform derived from the TARA Biosystems acquisition. This highlights the ongoing use and integration of TARA's cardiac modeling technology in Valo's R&D efforts to improve drug candidate selection and de-risking....more
Valo Health • January 19, 2022
Valo Health announced its acquisition of TARA Biosystems, Inc., a strategic move aimed at enhancing Valo's human-centric drug discovery capabilities. The integration of TARA's advanced cardiac tissue modeling technology with Valo's AI-driven Opal Computational Platform™ seeks to accelerate the development of novel therapeutics by providing more predictive, human-relevant data....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including TARA Biosystems, are just a search away.